Similar articles

• Synergistic interactions between vorinostat and sorafenib in chronic myelogenous leukemia cells involve Mcl-1 and p21CIP1 down-regulation.

  Dasmahapatra G, Yerram N, Dai Y, Dent P, Grant S. Dasmahapatra G, et al. Clin Cancer Res. 2007 Jul 15;13(14):4280-90. doi: 10.1158/1078-0432.CCR-07-0835. Clin Cancer Res. 2007. Retraction in: Clin Cancer Res. 2016 Oct 1;22(19):4959. doi: 10.1158/1078-0432.CCR-16-1914. PMID: 17634558 Retracted.
• Inhibition of MEK/ERK signaling induces apoptosis of acute myelogenous leukemia cells via inhibition of eukaryotic initiation factor 4E-binding protein 1 and down-regulation of Mcl-1.

  Nishioka C, Ikezoe T, Yang J, Yokoyama A. Nishioka C, et al. Apoptosis. 2010 Jul;15(7):795-804. doi: 10.1007/s10495-010-0483-y. Apoptosis. 2010. PMID: 20221697
• Temsirolimus downregulates p21 without altering cyclin D1 expression and induces autophagy and synergizes with vorinostat in mantle cell lymphoma.

  Yazbeck VY, Buglio D, Georgakis GV, Li Y, Iwado E, Romaguera JE, Kondo S, Younes A. Yazbeck VY, et al. Exp Hematol. 2008 Apr;36(4):443-50. doi: 10.1016/j.exphem.2007.12.008. Exp Hematol. 2008. PMID: 18343280
• The Bcl-xL inhibitor, ABT-737, efficiently induces apoptosis and suppresses growth of hepatoma cells in combination with sorafenib.

  Hikita H, Takehara T, Shimizu S, Kodama T, Shigekawa M, Iwase K, Hosui A, Miyagi T, Tatsumi T, Ishida H, Li W, Kanto T, Hiramatsu N, Hayashi N. Hikita H, et al. Hepatology. 2010 Oct;52(4):1310-21. doi: 10.1002/hep.23836. Hepatology. 2010. PMID: 20799354
• Blastic mantle cell lymphoma developing concurrently in a patient with chronic myelogenous leukemia and a review of the literature.

  Rodler E, Welborn J, Hatcher S, Unger K, Larkin E, Gumerlock PH, Wun T, Richman C. Rodler E, et al. Am J Hematol. 2004 Apr;75(4):231-8. doi: 10.1002/ajh.20025. Am J Hematol. 2004. PMID: 15054816 Review.